Profile data is unavailable for this security.
About the company
Erasca, Inc. is a clinical-stage precision oncology company. The Company is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The Company has assembled a wholly owned or controlled RAS/MAPK pathway-focused pipeline in the industry, which is focused on modality-agnostic programs aligned with its three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes three clinical-stage programs, such as a pan-RAF inhibitor, an ERK inhibitor, and a central nervous system (CNS)-penetrant EGFR inhibitor, and additional discovery-stage programs targeting other key oncogenic drivers. Its lead product candidate is naporafenib, a pan-RAF inhibitor with the potential for patients with NRAS-mutated (NRASm) melanoma, RAS Q61X solid tumors, and other RAS/MAPK pathway-driven tumors.
- Revenue in USD (TTM)0.00
- Net income in USD-125.04m
- Incorporated2018
- Employees126.00
- LocationErasca Inc10835 Road To The Cure, Suite 140SAN DIEGO 92121-1130United StatesUSA
- Phone+1 (858) 465-6511
- Fax+1 (302) 636-5454
- Websitehttps://www.erasca.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cerus Corp | 186.80m | -37.49m | 347.59m | 288.00 | -- | 6.47 | -- | 1.86 | -0.2086 | -0.2086 | 1.04 | 0.2905 | 0.8984 | 2.03 | 5.34 | 648,600.70 | -18.11 | -25.99 | -32.81 | -40.62 | 62.54 | 61.90 | -20.15 | -35.81 | 1.55 | -2.91 | 0.5989 | -- | -0.8061 | 19.69 | 12.37 | -- | 32.07 | -- |
| Sutro Biopharma Inc | 153.73m | -106.79m | 349.95m | 302.00 | -- | 1.74 | -- | 2.28 | -1.79 | -1.79 | 2.56 | 2.45 | 0.3503 | -- | 7.12 | 509,043.00 | -24.34 | -25.48 | -29.77 | -29.75 | -- | -- | -69.47 | -113.71 | -- | -- | 0.0264 | -- | 126.84 | 31.96 | 10.41 | -- | 22.61 | -- |
| Skye Bioscience Inc | 0.00 | -37.64m | 350.79m | 11.00 | -- | -- | -- | -- | -5.69 | -5.69 | 0.00 | -0.1726 | 0.00 | -- | -- | 0.00 | -357.65 | -232.67 | -- | -- | -- | -- | -- | -- | -- | -43.27 | 1.95 | -- | -- | -- | -93.23 | -- | 23.38 | -- |
| Tenaya Therapeutics Inc | 0.00 | -124.08m | 354.11m | 140.00 | -- | 2.21 | -- | -- | -1.68 | -1.68 | 0.00 | 2.04 | 0.00 | -- | -- | 0.00 | -55.21 | -- | -61.66 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -0.3388 | -- | -- | -- |
| Amarin Corporation plc (ADR) | 277.46m | -52.61m | 354.54m | 275.00 | -- | 0.6492 | -- | 1.28 | -0.1288 | -0.1288 | 0.679 | 1.33 | 0.3363 | 0.4197 | 2.23 | 1,008,927.00 | -6.38 | -4.48 | -8.90 | -6.54 | 63.61 | 75.70 | -18.96 | -8.59 | 1.93 | -- | 0.00 | -- | -16.87 | 6.01 | 44.13 | -- | 55.83 | -- |
| Rani Therapeutics Holdings Inc | 0.00 | -33.08m | 360.51m | 140.00 | -- | 46.62 | -- | -- | -1.29 | -1.29 | 0.00 | 0.1534 | 0.00 | -- | -- | 0.00 | -87.80 | -- | -140.92 | -- | -- | -- | -- | -- | -- | -28.75 | 0.6695 | -- | -- | -- | -11.06 | -- | -- | -- |
| Black Diamond Therapeutics Inc | 0.00 | -82.44m | 364.56m | 54.00 | -- | 3.07 | -- | -- | -1.92 | -1.92 | 0.00 | 2.26 | 0.00 | -- | -- | 0.00 | -52.37 | -40.29 | -58.91 | -43.29 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 9.57 | -- | -15.37 | -- |
| Harrow Inc | 130.19m | -24.41m | 365.14m | 315.00 | -- | 5.13 | -- | 2.80 | -0.7448 | -0.7448 | 3.99 | 2.01 | 0.5546 | 4.55 | 6.13 | 413,311.10 | -10.40 | -10.86 | -12.14 | -12.71 | 69.55 | 70.75 | -18.75 | -15.35 | 2.61 | 0.0445 | 0.7223 | -- | 46.95 | 25.77 | -73.30 | -- | 143.88 | -- |
| Aura Biosciences Inc | 0.00 | -76.41m | 366.05m | 88.00 | -- | 1.61 | -- | -- | -1.93 | -1.93 | 0.00 | 4.58 | 0.00 | -- | -- | 0.00 | -31.90 | -- | -33.50 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -30.03 | -- | -- | -- |
| Erasca Inc | 0.00 | -125.04m | 372.72m | 126.00 | -- | 1.03 | -- | -- | -0.8327 | -0.8327 | 0.00 | 2.10 | 0.00 | -- | -- | 0.00 | -27.48 | -- | -29.94 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 48.50 | -- | -- | -- |
| Alto Neuroscience Inc | 0.00 | -36.31m | 373.15m | 63.00 | -- | -- | -- | -- | -1.42 | -1.42 | 0.00 | 2.73 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.1238 | -- | -- | -- | -31.02 | -- | -- | -- |
| Esperion Therapeutics Inc | 229.74m | -86.51m | 386.38m | 240.00 | -- | -- | -- | 1.68 | -1.00 | -1.00 | 1.76 | -1.57 | 0.7353 | 0.7415 | 5.05 | 957,250.00 | -27.69 | -69.45 | -47.42 | -101.81 | 81.85 | -- | -37.65 | -147.44 | 1.78 | -0.6581 | -- | -- | 54.14 | -- | 10.45 | -- | -- | -- |
| Solid Biosciences Inc | 0.00 | -96.02m | 388.07m | 88.00 | -- | 1.65 | -- | -- | -4.84 | -4.84 | 0.00 | 6.20 | 0.00 | -- | -- | 0.00 | -45.16 | -49.99 | -49.47 | -56.25 | -- | -- | -- | -2,117.05 | -- | -- | 0.0133 | -- | -100.00 | -- | -11.67 | -- | -27.90 | -- |
| Terns Pharmaceuticals Inc | 0.00 | -90.21m | 391.28m | 66.00 | -- | 1.53 | -- | -- | -1.27 | -1.27 | 0.00 | 3.95 | 0.00 | -- | -- | 0.00 | -32.48 | -41.34 | -33.72 | -45.70 | -- | -- | -- | -31,010.30 | -- | -- | 0.00 | -- | -- | -- | -49.49 | -- | -26.60 | -- |
| Biomea Fusion Inc | 0.00 | -127.27m | 397.91m | 110.00 | -- | 2.94 | -- | -- | -3.57 | -3.57 | 0.00 | 3.77 | 0.00 | -- | -- | 0.00 | -90.54 | -- | -107.35 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -43.29 | -- | -- | -- |
| Tourmaline Bio Inc | 0.00 | -42.12m | 398.80m | 44.00 | -- | 1.54 | -- | -- | -10.18 | -10.18 | 0.00 | 10.08 | 0.00 | -- | -- | 0.00 | -20.85 | -- | -21.74 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 42.99 | -- | -- | -- |
Data as of May 09 2024. Currency figures normalised to Erasca Inc's reporting currency: US Dollar USD
23.16%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Armistice Capital LLCas of 31 Dec 2023 | 8.10m | 5.36% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 6.57m | 4.35% |
| Invus Public Equities Advisors LLCas of 31 Dec 2023 | 4.72m | 3.13% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 3.68m | 2.44% |
| PFM Health Sciences LPas of 31 Dec 2023 | 2.58m | 1.71% |
| Renaissance Technologies LLCas of 31 Dec 2023 | 2.01m | 1.33% |
| Schroder Investment Management Ltd.as of 31 Dec 2023 | 1.93m | 1.28% |
| SV Health Managers LLPas of 30 Sep 2023 | 1.93m | 1.28% |
| Geode Capital Management LLCas of 31 Dec 2023 | 1.81m | 1.20% |
| SSgA Funds Management, Inc.as of 31 Dec 2023 | 1.67m | 1.10% |
More ▼
Data from 30 Sep 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
